Last reviewed · How we verify
NCT05970471: IMPLICATION
Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital
trial in Preference, Patient in 167 participants. Completed in 4 December 2025.
4 December 2025
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Besancon |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 167 |
| Start date | 10 August 2023 |
| Primary completion | 4 December 2025 |
| Estimated completion | 4 December 2025 |
| Sites | 1 location across France |
Conditions studied
- Preference, Patient — all drugs for Preference, Patient →
- Pharmacist-Patient Relations — all drugs for Pharmacist-Patient Relations →
- Caregiver — all drugs for Caregiver →
- Cancer — all drugs for Cancer →
Sponsor
Centre Hospitalier Universitaire de Besancon
Who can join
18 and older, any sex, with Preference, Patient or Pharmacist-Patient Relations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To ensure the safe use of oral anticancer drugs, oncology pharmacy consultations (OPCs) have been established in France. Their goal is to provide the patient with the means to identify, prevent and limit adverse effects and to know who to refer to in case of a serious adverse effect, perform a pharmaceutical analysis of the prescription, and participate in the improvement and evaluation of overall compliance. OPCs are conditioned by the needs, expectations, and involvement of the patients in their care. In healthcare, patients are increasingly encouraged to play an active role in the knowledge and management of their health, express their concerns and preferences, and participate in medical decisions. Thus, it is essential to elicit their preferences. The discrete-choice experiment (DCE) is the validated and recommended method of the International Society for Pharmacoeconomics and Outcomes Research for such a task.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05970471
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Preference, Patient
Currently open trials in the same condition.
- NCT06046625 — Needs and Preferences of Patients With Head-neck Cutaneous SCC · active not recruiting
Other Centre Hospitalier Universitaire de Besancon trials
Trials by the same sponsor.
- NCT07492199 — High Depth Exome Sequencing on DNA From a Salivary Sample by Mouth Smear. · not yet recruiting
- NCT07438015 — VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit · NA · not yet recruiting
- NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
- NCT06864065 — Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder · NA · recruiting
- NCT07067762 — Botulinum Toxin Injections Into the Salivary Glands of Cerebrospinal Children With Chronic Sialorrhea · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05970471 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Besancon
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05970471.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing